Use filters to refine the search results.
Results 1-3 of 3
|26-May-2017||De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial||Clark, RE; Polydoros, F; Apperley, JF; Milojkovic, D; Pocock, C, et al|
|11-May-2017||E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor therapy.||Claudiani, S; Apperley, J; Gale, RP; Clark, R; Szydlo, R, et al|
|28-Jul-2016||Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia||Claudiani, S; Apperley, JF; Deplano, S; Khorashad, J; Foroni, L, et al|